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819-4 Obesity Predicts Coronary Endothelial Dysfunction 
Independently of Inflammation, Atherosclerosis, and 
Conventional Risk Factors
Julian Halcox, Gloria Zalos, Marietta Charakida, Arshed A. Quyyumi, National Institutes 
of Health, Bethesda, MD, Institute of Child Health, London, United Kingdom
Background: Obesity is a well recognized modifiable risk factor for coronary artery dis-
ease (CAD) that is associated with insulin resistance, dyslipidemia, hypertension and
low-grade inflammation. We investigated the relationship between coronary vascular
endothelial dysfunction, obesity and its metabolic correlates.
Methods: Coronary vascular function testing was performed in 418 patients (203 with
normal coronary arteries). Change in coronary blood flow (dCBF) was measured using a
Doppler flowire during intra-coronary acetylcholine (15mg/min), and adenosine (2.2mg/
min) infusion to test endothelium-dependent, and -independent coronary microvascular
function. Patients were grouped according to body mass index (BMI); group 1 (<25kg/m2,
n=90), group 2 (25-30kg/m2, n=163), group 3 (>30kg/m2, n=164).
Results: Prevalence of diabetes and hypertension, as well as total cholesterol, low den-
sity lipoprotein, and triglyceride levels were increased, whereas high density lipoprotein
was lower with increasing BMI. C-reactive protein (CRP) was elevated in group 3 com-
pared with 1 and 2 (1.15±0.73 Versus 0.74±0.67 and 0.74±0.57mg/dl respectively,
p<0.001). During acetylcholine administration, dCBF was reduced with increasing BMI
(135±102, 104±101, and 95±88% in groups 1-3 respectively, p=0.009), whereas dCBF
was similar during adenosine infusion (377±152, 363±173, and 358±186% in groups 1-3
respectively p=0.67). The association between BMI group and dCBF with acetylcholine
was independent of CAD and its risk factors, including CRP, by multivariable analysis
(p<0.05). Furthermore, reduced dCBF with acetylcholine was also observed in the cohort
of obese subjects with normal coronary arteries (135±95, Versus 102±84% in groups 1
and 3 respectively, p=0.01).
Conclusion: The relationship between obesity and coronary vascular endothelial dys-
function remains independent of the associated adverse CAD risk factor profile. Thus,
weight loss may improve CAD risk over and above the observed benefits on conventional
risk factors.
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819-5 Atorvastatin Restores Endothelial Function in 
Normocholesterolemic Smokers
Joshua Beckman, James K. Liao, Shauna Hurley, Debi Mitra, Mark A. Creager, Brigham 
and Women's Hospital, Boston, MA
Cigarette smoking impairs endothelial function and is a major cause of atherosclero-
sis.Research suggests that statins benefit vascular function independent of their lipid
lowering effects. We hypothesized that statin therapy would improve endothelial function
in normocholesterolemic smokers. We performed a randomized, double-blind, crossover,
placebo-controlled study of atorvastatin (Atorva), 40 mg daily, in 20 smokers (S) and 20
healthy subjects (H). Subjects had vascular function testing and skin biopsy after each 30
day treatment. Ultrasonography was used to measure brachial artery flow-mediated,
endothelium-dependent vasodilation (EDV) and nitroglycerin-induced (0.4 mg) endothe-
lium-independent vasodilation (EIV). To determine mechanisms of the findings skin
endothelial NO synthase (eNOS) mRNA expression was assessed by RT-PCR and nor-
malized to GAPDH. Skin nitrotyrosine concentration, an intracellular marker of oxidative
stress, was determined via enzyme immunosorbent assay. The mean age (42 vs. 38 y),
total cholesterol (188 vs. 176 mg/dl), LDL (103 vs. 95 mg/dl), and HDL (54 vs. 54 mg/dl)
(all p>0.1) were similar in S and H, respectively. EDV was less in S compared with H
(8.0% vs. 12.1%, p = .003), but there was no difference in EIV (18.6% vs. 21.0%, p =
.34). Atorva restored EDV in S (8.0% to 10.5%, p = .017), but had no effect in H (12.1%
to. 11.0%, p = .37). Atorva did not affect EIV in either group. Atorva decreased total and
LDL cholesterol in both groups, but there was no relationship between the change in total
or LDL cholesterol and EDV. Skin eNOS mRNA was higher in S than H (.77 vs. .56, p =
.04), suggesting that eNOS content was not responsible for impaired EDV in S. Atorva
increased eNOS content in H (.56 vs. .62, p = .026), but not in S (.77 vs. .77, p = .95).
Nitrotyrosine concentration was higher in S than H (82.4 vs. 38.1, p = .05), indicative of
increased oxidative stress, but did not change with Atorva. Conclusion: Atorva restores
endothelial function in normocholesterolemic smokers, independent of LDL lowering.
Improved NO bioavailability with statin, may result from eNOS activity changes, since it
cannot be ascribed to changes in eNOS content or reduction in oxidative stress.
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819-6 Inducible Nitric Oxide Synthase Activity Does Not 
Contribute to the Maintenance of Peripheral Vascular 
Tone in Patients With Symptomatic Congestive Heart 
Failure
Anna R. Dover, Stanley Chia, Nicholas L. Cruden, James W. Ferguson, Keith A. Fox, 
David E. Newby, University of Edinburgh, Edinburgh, United Kingdom
Background: There have been previous reports of inducible nitric oxide synthase (iNOS)
activity in the peripheral vasculature of patients with symptomatic congestive heart failure
(CHF). However, these studies used the poorly selective inhibitor, aminoguanidine, which
has considerable action on endothelial nitric oxide synthase (eNOS). For the first time,
we have used the highly selective iNOS inhibitor, 1400W, (~10,000-fold more selective for
iNOS than for eNOS) to determine whether iNOS activity contributes to the maintenance
of vascular tone in patients with symptomatic CHF.
Methods: Bilateral forearm blood flow was recorded using strain-gauge plethysmogra-
phy in 10 patients with CHF (New York Heart Association Class II-IV) during intra-bra-
chial infusion of 1400W (0.1-1 µmol/min), NG-monomethyl-L-arginine (L-NMMA, a non-
selective NOS inhibitor; 2-8 µmol/min) and norepinephrine (as a control vasoconstrictor;
60-480 pmol/min).
Results: There were no changes in heart rate, mean arterial pressure or non-infused
forearm blood flow during drug infusions. Intra-brachial infusion of L-NMMA and norepi-
nephrine caused dose dependent reductions in infused forearm blood flow (p<0.05 for
both): peak reductions of 28±4% and 48±6% respectively. In contrast, 1400W had no
effect on blood flow: -2±3% change with 1400W at 1 µmol/min (95% confidence intervals,
-7 to 3%, p=ns).
Conclusion: In contrast to earlier reports, we have found that selective iNOS inhibition
does not affect forearm blood flow in patients with CHF. These findings suggest that the
effects on vascular tone seen after administration of poorly selective NOS inhibitors may
be largely due to inhibition of eNOS. Inducible NOS activity does not appear to contribute
to the maintenance of peripheral vascular tone in patients with symptomatic CHF.
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820-1 Comparative Effects of Statins on Atherogenic 
Dyslipidemia in Patients With the Metabolic Syndrome
Prakash Deedwania, Donald Hunninghake, The STELLAR Study Group, University of 
California-San Francisco, Fresno, CA, University of Minnesota, Minneapolis, MN
Background: Atherogenic dyslipidemia is a major modifiable aspect of the metabolic
syndrome. We assessed the effects of rosuvastatin, atorvastatin, simvastatin, and prav-
astatin on lipids in adult hypercholesterolemic (low-density lipoprotein cholesterol [LDL-
C] >160 mg/dL and <250 mg/dL; triglycerides [TG] <400 mg/dL) patients with the meta-
bolic syndrome.
Methods: These patients from the Statin Therapies for Elevated Lipid Levels compared
Across doses to Rosuvastatin (STELLAR) trial (4522IL/0065) met >3 of 5 of the National
Cholesterol Education Program metabolic syndrome criteria, with body mass index >30
kg/m2 substituted for the waist circumference criterion. Treatments for 6 weeks were
rosuvastatin 10, 20, or 40 mg, atorvastatin 10, 20, 40, or 80 mg, simvastatin 10, 20, 40,
or 80 mg, or pravastatin 10, 20, or 40 mg. Rosuvastatin was compared statistically with
equivalent or higher doses of the comparators (significance level adjusted to account for
multiple comparisons).
Results: Out of 2268 patients, 811 met these criteria. Mean baseline values were 190
mg/dL for LDL-C and 215 mg/dL for TG. Reductions from baseline were 44-55%, 37-
50%, 28-47%, and 20-29% for LDL-C, and 22-34%, 23-33%, 15-23%, and 12-15% for
TG, with rosuvastatin, atorvastatin, simvastatin, and pravastatin, respectively. The table
shows high-density lipoprotein (HDL)-C and non-HDL-C. 
Conclusion: Rosuvastatin had the most favorable effect on the atherogenic dyslipidemia 
associated with the metabolic syndrome.
Overall baselines and least-square mean % changes from baseline in non-HDL-C and 
HDL-C
Rosuvastatin
(n=49-61/group)
Atorvastatin
(n=48-65/group)
Simvastatin
(n=49-62/group)
Pravastatin
(n=58-69/group)
Non-
HDL-C
HDL-C Non-
HDL-C
HDL-C Non-
HDL-C
HDL-C Non-
HDL-C
HDL-C
Baseline,
mg/dL
234 45 234 44 231 44 231 44
10 mg –40 +7.6 –34 +7.2 –26a +8.3 –19a +3.3
20 mg –48 +11.1 –38b +9.4 –35b +9.5 –21ab +6.9
40 mg –52 +10.4 –46 +5.0 –36bc +8.0 –27abc +6.4
80 mg –46 +4.7b –42c +10.0
Significantly different (p<.002) compared with (a)rosuvastatin 10 mg, (b)rosuvastatin 20 
mg, (c)rosuvastatin 40 mg
